Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer

Current Cancer Drug Targets

Volumn 8, Issue 5, 2008, Pages 367-377

  Chen, George G ^a   Vlantis, Alexander C ^a   Zeng, Qiang ^a   Van Hasselt, C Andrew ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apoptosis; Cancer; Estrogen; Estrogen receptors; Proliferation; Thyroid

Indexed keywords

2 HYDROXYESTRADIOL; 4 HYDROXYESTRADIOL; 4 HYDROXYTAMOXIFEN; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CAVEOLIN 1; DIETHYLSTILBESTROL; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA AGONIST; FULVESTRANT; GENISTEIN; HORMONE RECEPTOR STIMULATING AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN SHC; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER INCIDENCE; CELL GROWTH; CELL PROLIFERATION; CELLULAR DISTRIBUTION; DOWN REGULATION; DRUG TARGETING; ENDOMETRIUM TUMOR; ENZYME ACTIVITY; ESTROGEN ACTIVITY; GENE MUTATION; GENOTOXICITY; HUMAN; LIGAND BINDING; MALIGNANT TRANSFORMATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; RECEPTOR AFFINITY; REGULATORY MECHANISM; REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; THYROID CANCER;

ANTINEOPLASTIC AGENTS, HORMONAL; CELL PROLIFERATION; ESTROGENS; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 48849088148     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908785133150     Document Type: Review

References (117)

1. Correa, P.; Chen, V. W. Endocrine gland cancer. Cancer 1995, 75(Suppl. 1), 338-352.
2. Libutti, S. K. Understanding the role of gender in the incidence of thyroid cancer. Cancer J. 2005, 11, 104-105.
3. Smailyte, G.; Miseikyte-Kaubriene, E.; Kurtinaitis, J. Increasing thyroid cancer incidence in Lithuania in 1978-2003. BMC Cancer 2006, 6, 284-289.
4. Scheiden, R.; Keipes, M.; Bock, C.; Dippel, W.; Kieffer, N.; Capesius, C. Thyroid cancer in Luxembourg: a national population-based data report (1983-1999). BMC Cancer 2006, 6, 102-111.
5. Machens, A.; Hauptmann, S.; Dralle, H. Disparities between male and female patients with thyroid cancers: sex difference or gender divide? Clin. Endocrinol. 2006, 65, 500-505.
6. Ward, L. S.; Assumpcao, L. V. The impact of gender in differentiated thyroid cancer. Clin. Endocrinol. 2007, 66, 752.
7. Ron, E.; Kleinerman, R. A.; Boice Jr, J. D.; Livolsi, V. A.; Flannery, J. T.; Fraumeni, J. F. A population-based case-control study of thyroid cancer. J. Natl. Cancer Inst. 1987, 79, 1-12.
8. Preston-Martin, S.; Bernstein, L.; Pike, M. C.; Maldonado, A. A.; Henderson, B. E. Thyroid cancer among young women related to prior thyroid disease and pregnancy history. Br. J. Cancer 1987, 55, 191-195.
9. McTiernan, A. M.; Weiss, N. S.; Daling, J. R. Incidence of thyroid cancer in women in relation to previous exposure to radiation therapy and history of thyroid disease. J. Natl. Cancer Inst. 1984, 73, 575-581.
10. Persson, I.; Yuen, J.; Bergkvist, L.; Schairer, C. Cancer incidence and mortality in women receiving estrogen and estrogen- progestin replacement therapy-long-term follow-up of a Swedish cohort. Int. J. Cancer 1996, 67, 327-332.
11. Cady, B.; Sedgwick, C. E.; Meissner, W. A.; Wool, M. S.; Salzman, F. A.; Werber, J. Risk factor analysis in differentiated thyroid cancer. Cancer 1979, 43, 810-820.
12. Thiruvengadam, A.; Govindarajulu, P.; Aruldhas, M. M. Modulatory effect of estradiol and testosterone on the development of N-nitrosodiisopropanolamine induced thyroid tumors in female rats. Endocrine Res. 2003, 29, 43-51.
13. Mori, M.; Naito, M.; Watanabe, H.; Takeichi, N.; Dohi, K.; Ito, A. Effects of sex difference, gonadectomy, and estrogen on N-methyl-N-nitrosourea induced rat thyroid tumors. Cancer Res. 1990, 50, 7662-7667.
14. Stender, J. D.; Frasor, J.; Komm, B.; Chang, K. C.; Kraus, W. L.; Katzenellenbogen, B. S. Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mole. Endocrinol. 2007, 21, 2112-2123.
15. Arnold, J. T.; Liu, X.; Allen, J. D.; Le, H.; McFann, K. K.; Blackman, M. R. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate 2007, 67, 1152-1162.
16. Lee, M. L.; Chen, G. G.; Vlantis, A. C.; Tse, G. M.; Leung, B. C.; van Hasselt, C. A. Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL. Cancer J. 2005, 11, 113-121.
17. Cavalieri, E. L.; Stack, D. E.; Devanesan, P. D.; Todorovic, R.; Dwivedy, I.; Higginbotham, S.; Johansson, S. L.; Patil, K. D.; Gross, M. L.; Gooden, J. K.; Ramanathan, R.; Cerny, R. L.; Rogan, E. G. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators, Proc. Natl. Acad. Sci. USA 1997, 99, 10937-10942.
18. Faucher, F.; Lacoste, L.; Luu-The, V. Human type 1 estrogen sulfotransferase: catecholestrogen metabolism and potential involvement in cancer promotion. Ann. N.Y. Acad. Sci. 2002, 963, 221-228.
19. Fernandez, S. V.; Russo, I. H.; Lareef, M.; Balsara, B.; Russo, J. Comparative genomic hybridization of human breast epithelial cells transformed by estrogen and its metabolites. Int. J. Oncol. 2005, 26, 691-695.
20. Chakravarti, D.; Mailander, P.; Li, K.-M.; Higginbotham, S.; Zhang, H. L.; Gross, M. L.; Meza, J. L.; Cavalieri E. L.; Rogan, E. G. Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene, Oncogene 2001, 20, 7945-7953.
21. Herrmann, B. L.; Saller, B.; Janssen, O. E.; Gocke, P.; Bockisch, A.; Sperling, H.; Mann, K.; Broecker, M. Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J. Clin. Endocrinol. Metab. 2002, 87, 5476-5484.
22. Starr, J. R.; Chen, C.; Doody, D. R.; Hsu, L.; Ricks, S.; Weiss, N. S.; Schwartz, S. M. Risk of testicular germ cell cancer in relation to variation in maternal and offspring cytochrome p450 genes involved in catechol estrogen metabolism. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 2183-2190.
23. Hontz, A. E.; Li, S. A.; Lingle, W. L.; Negron, V.; Bruzek, A.; Salisbury, J. L.; Li, J. J. Aurora a and B overexpression and centrosome amplification in early estrogen-induced tumor foci in the Syrian hamster kidney: implications for chromosomal instability, aneuploidy, and neoplasia. Cancer Res. 2007, 67, 2957-2963.
24. Tsutsui, S.; Ohno, S.; Murakami, S.; Hachitanda, Y.; Oda, S. DNA aneuploidy in relation to the combination of analysis of estrogen receptor, progesterone receptor, p53 protein and epidermal growth factor receptor in 498 breast cancers. Oncology 2002, 63, 48-55.
25. Epe, B.; Harttig, U.; Stopper, H.; Metzler, M. Covalent binding of reactive estrogen metabolites to microtubular protein as a possible mechanism of aneuploidy induction and neoplastic cell transformation. Environ. Health Perspect. 1990, 88, 123-127.
26. Speroff, L.; Glass, R. H.; Kase, N. G. Clin. Gynecol. Endocrinol. Infert. (6th ed). Lippincott Williams & Wilkins: Philadelphia, 1999.
27. Ruggiero, R. J.; Likis, F. E. Estrogen: physiology, pharmacology, and formulations for replacement therapy. J. Midwifery Womens Health 2002, 47, 130-138.
28. Jones, K. P. Estrogens and progestins: what to use and how to use it. Clin. Obstet. Gynecol. 1992, 32, 871-883.
29. Dalla Valle, L.; Ramina, A.; Vianello, S.; Fassina, A.; Belvedere, P.; Colombo, L. Potential for estrogen synthesis and action in human normal and neoplastic thyroid tissues. J. Clin. Endocrinol. Metab. 1998, 83, 3702-3709.
30. Lima, L. P.; Barros, I. A.; Lisboa, P. C.; Araujo, R. L.; Silva, A. C.; Rosenthal, D.; Ferreira, A. C.; Carvalho, D. P. Estrogen effects on thyroid iodide uptake and thyroperoxidase activity in normal and ovariectomized rats. Steroids 2006, 71, 653-659.
31. Marqusee, E.; Braverman, L. E.; Lawrence, J. E.; Carroll, J. S.; Seely, E. W. The effect of droloxifene and estrogen on thyroid function in postmenopausal women. J. Clin. Endocrinol. Metab. 2000, 85, 4407-4410.
32. Ceresini, G.; Milli, B.; Morganti, S.; Maggio, M.; Bacchi-Modena, A.; Sgarabotto, M. P.; Chirico, C.; Di Donato, P.; Campanati, P.; Valcavi, R.; Ceda, G. P.; Braverman, L. E.; Valenti, G. Effect of estrogen therapy for 1 year on thyroid volume and thyroid nodules in postmenopausal women. Menopause 2008, 15(2), 326-331.
33. Deroo, B. J.; Korach, K. S. Estrogen receptors and human disease. J. Clin. Invest. 2006, 116, 561-570.
34. Enmark, E.; Pelto-Huikko, M.; Grandien, K.; Lagercrantz, S.; Lagercrantz, J.; Fried, G.; Nordenskjold, M.; Gustafsson, J. A. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J. Clin. Endocrinol. Metab. 1997, 82, 4258-4265.
35. Menasce, L. P.; White, G. R.; Harrison, C. J.; Boyle, J. M. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics 1993, 17, 263-265.
36. Kelley, S. T.; Thackray, V. G. Phylogenetic analyses reveal ancient duplication of estrogen receptor isoforms, J. Mol. Evol. 1999, 49, 609-614.
37. Kuiper, G. G.; Lemmen, J. G.; Carlsson, B.; Corton, C. J.; Safe, S. H.; van der Saag, P. T.; van der Burg, B; Gustafsson, J-A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinol. 1998, 139, 4252-4263.
38. Kuiper, G. G.; Carlsson, B.; Grandien, K.; Fujimori, K.; Naganuma, H.; Inoue, S.; Kinouchi, Y.; Kameyama, K.; Takami, H.; Shimosegawa, T.; Sasano, H. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinol. 1997, 138, 863-870.
39. Gustafsson, J. A. Estrogen receptor beta - a new dimension in estrogen mechanism of action. J. Endocrinol. 1999, 163, 379-383.
40. Taylor, A. H.; Al-Azzawi, F. Immunolocalisation of oestrogen receptor beta in human tissues. J. Mol. Endocrinol. 2000, 24, 145-155.
41. Ascenzi, P.; Bocedi, A.; Marino, M. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol. Aspects Med. 2006, 27, 299-402.
42. Hiroi, H.; Inoue, S.; Watanabe, T.; Goto, W.; Orimo, A.; Momoeda, M.; Tsutsumi, O.; Taketani, Y.; Muramatsu, M. Differential immunolocalization of estrogen receptor alpha and beta in rat ovary and uterus. J. Mol. Endocrinol. 1999, 22, 37-44.
43. Sar, M.; Welsch, F. Differential expression of estrogen receptor-beta and estrogen receptor-alpha in the rat ovary. Endocrinol. 1999, 140, 963-971.
44. Weihua, Z.; Warner, M.; Gustafsson, J. A. Estrogen receptor beta in the prostate. Mol. Cell. Endocrinol. 2002, 193, 1-5.
45. Ihionkhan, C. E.; Chambliss, K. L.; Gibson, L. L.; Hahner, L. D.; Mendelsohn, M. E.; Shaul, P. W. Estrogen causes dynamic alterations in endothelial estrogen receptor expression. Circ. Res. 2002, 91, 814-820.
46. Matthews, J.; Gustafsson, J. A. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol. Interv. 2003, 3, 281-292.
47. Hampl, R.; Nmec, J.; Heresova, J.; Kimlova, I.; Starka, L. Estrogen receptors in human goitrous and neoplastic thyroid. Endocrinol. Exp.1985, 19, 227-230.
48. Hiasa, Y.; Nishioka, H.; Kitahori, Y.; Yane, K.; Nakaoka, S.; Ohshima, M.; Konishi, N.; Nishii, K.; Kitamura, M.; Sugimura, M. Immunohistochemical detection of estrogen receptors in paraffin sections of human thyroid tissues. Oncology 1991, 48, 421-424.
49. Metaye, T.; Millet, C.; Kraimps, J. L.; Aubouin, B.; Barbier, J.; Begon, F. Estrogen receptors and cathepsin D in human thyroid tissue. Cancer 1993, 72, 1991-1996.
50. Chaudhuri, P. K.; Prinz, R. Estrogen receptor in normal and neoplastic human thyroid tissue. Am. J. Otolaryngol. 1989, 10, 322-326.
51. Tavangar, S. M.; Monajemzadeh, M.; Larijani, B.; Haghpanahm, V. Immunohistochemical study of oestrogen receptors in 351 human thyroid glands. Singapore Med. J. 2007, 48, 744-747.
52. Egawa, C.; Miyoshi, Y.; Iwao, K.; Shiba, E.; Noguchi, S. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in normal and malignant thyroid tissues by real-time polymerase chain reaction. Oncology 2001, 61, 293-298.
53. Taylor, A. H.; Al-Azzawi, F. Immunolocalisation of oestrogen receptor beta in human tissues. J. Mol. Endocrinol. 2000, 24, 145-155.
54. Bléchet, C.; Lecomte, P.; De Calan, L.; Beutter, P.; Guyétant, S. Expression of sex steroid hormone receptors in C cell hyperplasia and medullary thyroid carcinoma. Virchows Arch. 2007, 450, 433-439.
55. Kawabata, W.; Suzuki, T.; Moriya, T.; Fujimori, K.; Naganuma, H.; Inoue, S.; Kinouchi, Y.; Kameyama, K.; Takami, H.; Shimosegawa, T.; Sasano, H. Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders: possible in situ estrogen synthesis and actions. Modern Pathol. 2003, 16, 437-444.
56. Ceresini, G.; Morganti, S.; Graiani, V.; Saccani, M.; Milli, B.; Usberti, E.; Valenti, G.; Ceda, G. P.; Corcione L. Estrogen receptor (ER)-beta, but not ER-alpha, is present in thyroid vessels: immunohistochemical evaluations in multinodular goiter and papillary thyroid carcinoma. Thyroid 2006, 16, 1215-1220.
57. Losel, R. M.; Falkenstein, E.; Feuring, M.; Schultz, A.; Tillmann, H. C.; Rossol-Haseroth, K.; Wehling, M. Nongenomic steroid action: controversies, questions, and answers. Physiol. Rev. 2003, 83, 965-1016.
58. Lu, Q.; Ebling, H.; Mittler, J.; Baur, W. E.; Karas, R. H. MAP kinase mediates growth factor-induced nuclear translocation of estrogen receptor alpha. FEBS Lett. 2002, 516, 1-8.
59. Zeng, Q.; Chen, G. G.; Vlantis, A. C.; van Hasselt, C. A. Estrogen mediates the growth of human thyroid carcinoma cells via an estrogen receptor - ERK pathway. Cell Prolif. 2007, 40, 921-935.
60. Jaklic, B. R.; Rushin, J.; Ghosh, B. C. Estrogen and progesterone receptors in thyroid lesions. Ann. Surg. Oncol. 1995, 2, 429-434.
61. Arain, S. A.; Shah, M. H.; Meo, S. A. Jamal, Q. Estrogen receptors in human thyroid gland. An immunohistochemical study. Saudi Med. J. 2003, 24, 174-178.
62. Manole, D.; Schildknecht, B.; Gosnell, B.; Adams, E.; Derwahl, M. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms. J. Clin. Endocrinol. Metab. 2001, 86, 1072-1077.
63. Razandi, M.; Pedram, A.; Greene, G. L.; Levin, E. R. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol. Endocrinol. 1999, 13, 307-319.
64. Zhang, Z.; Kumar, R.; Santen, R. J.; Song, R. X. The role of adapter protein Shc in estrogen non-genomic action. Steroids 2004, 69, 523-529.
65. Zeng, Q.; Chen, G. G.; Vlantis, A. C.; Tse, G. M.; van Hasselt, C. A. Different contributions of estrogen receptor risoforms to the development of thyroid papillary and anaplastic cancers. J. Pathol. 2008, 214, 425-433.
66. Furlanetto, T. W.; Nguyen, L. Q.; Jameson, J. L. Estradiol increases proliferation and down-regulates the sodium/iodide symporter gene in FRTL-5 cells. Endocrinology 1999, 140, 5705-5711.
67. Inoue, H.; Oshimo, K.; Miki, H.; Kawano, M.; Monden, Y. Immunohistochemical study of estrogen receptors and the responsiveness to estrogen in papillary thyroid carcinoma. Cancer 1993, 72, 1364-1368.
68. Brunelli, E.; Minassi, A.; Appendino, G.; Moro, L. 8-Prenylnaringenin, inhibits estrogen receptor-alpha mediated cell growth and induces apoptosis in MCF-7 breast cancer cells. J. Steroid Biochem. Mol. Biol. 2007, 107, 140-148.
69. Reddy, K. B.; Glaros, S. Inhibition of the MAP kinase activity suppresses estrogen-induced breast tumor growth both in vitro and in vivo. Int. J. Oncol. 2007, 30, 971-975.
70. Yamaguchi, Y. Microenvironmental regulation of estrogen signals in breast cancer. Breast Cancer 2007, 14, 175-181.
71. Chan, E. K.; Sepkovic, D. W.; Yoo Bowne, H. J.; Yu, G. P.; Schantz, S. P. A hormonal association between estrogen metabolism and proliferative thyroid disease. Otolaryngol. Head Neck Surg. 2006, 134, 893-900.
72. Russo, J.; Russo, I. H. The role of estrogen in the initiation of breast cancer. J. Steroid Biochem. Mol. Biol. 2006, 102, 89-96.
73. Roque, L.; Rodrigues, R.; Pinto, A.; Moura-Nunes, V.; Soares, J. Chromosome imbalances in thyroid follicular neoplasms: a comparison between follicular adenomas and carcinomas. Genes. Chromosomes Cancer 2003, 36, 292-302.
74. McCarthy, R. P.; Wang, M.; Jones, T. D.; Strate, R. W.; Cheng, L. Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas. Clin. Cancer Res. 2006, 12, 2414-2418.
75. Kitamura, Y.; Shimizu, K.; Tanaka, S.; Ito, K.; Emi, M. Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q. Genes Chromosomes Cancer 2000, 27, 244-251.
76. Kitamura, Y.; Shimizu, K.; Tanaka, S.; Ito, K.; Emi, M. Association of allelic loss on 1q, 4p, 7q, 9p, 9q, and 16q with postoperative death in papillary thyroid carcinoma. Clin. Cancer Res. 2000, 6, 1819-1825.
77. Kjellman, P.; Lagercrantz, S.; Hoog, A.; Wallin, G.; Larsson, C.; Zedenius, J. Gain of 1q and loss of 9q21.3-q32 are associated with a less favorable prognosis in papillary thyroid carcinoma. Genes, Chromosomes Cancer 2001, 32, 43-49.
78. Riggins, R. B.; Bouton, A. H.; Liu, M. C.; Clarke, R. Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam. Horm. 2005, 71, 201-237.
79. Hail Jr, N.; Carter, B. Z.; Konopleva, M.; Andreeff, M. Apoptosis effector mechanisms: a requiem performed in different keys. Apoptosis 2006, 11, 889-904.
80. Cho, M. A.; Lee, M. K.; Nam, K. H.; Chung, W. Y.; Park, C. S.; Lee, J. H.; Noh, T.; Yang, W. I.; Rhee, Y.; Lim, S. K.; Lee, H. C.; Lee, E. J. Expression and role of estrogen receptor {alpha} and {beta} in medullary thyroid carcinoma: different roles in cancer growth and apoptosis. J. Endocrinol. 2007, 195, 255-63.
81. Ali, S.; Coombes, R. C. Estrogen receptor alpha in human breast cancer: occurrence and significance. J. Mammary Gland. Biol. Neoplasia 2000, 5, 271-281.
82. Smith, F. B.; Puerto, C. D.; Sagerman P. Relationship of estrogen and progesterone receptor protein levels in carcinomatous and adjacent non-neoplastic epithelium of the breast: a histopathologic and image cytometric study. Breast Cancer Res. Treat. 2001, 65, 241-247.
83. Leygue, E.; Dotzlaw, H.; Watson, P. H.; Murphy, L. C. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res. 1998, 58, 3197-3201.
84. Lazennec, G.; Bresson, D.; Lucas A.; Chauveau, C.; Vignon, F. ERβ inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001, 142, 4120-4130.
85. Helguero, L. A.; Faulds, M. H.; Gustafsson, J. A.; Haldosen, L. A. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 2005, 24, 6605-6616.
86. Sayeed, A.; Konduri, S. D.; Liu, W.; Bansal, S.; Li, F.; Das, G. M. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res. 2007, 67, 7746-7755.
87. Rao, B. R.; Slotman, B. J. Endocrine factors in common epithelial ovarian cancer. Endocr. Rev. 1991, 12, 14-26.
88. Mosselman, S.; Polman, J.; Dijkema, R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996, 392, 49-53.
89. Cunat, S.; Hoffmann, P.; Pujol, P. Estrogens and epithelial ovarian cancer. Gynecol. Oncol. 2004, 94, 25-32.
90. Foley, E. F.; Jazaeri, A. A.; Shupnik, M. A.; Jazaeri, O.; Rice, L. W. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res. 2000, 60, 245-248.
91. Antonsson, B.; Martinou, J. -C. The Bcl-2 protein family. Exp. Cell. Res. 2000, 256, 50-57.
92. Kossmehl, P.; Shakibaei, M.; Cogoli, A.; Infanger, M.; Curcio, F.; Schonberger, J.; Eilles, C.; Bauer, J.; Pickenhahn, H.; Schulze-Tanzil, G.; Paul, M.; Grimm, D. Weightlessness induced apoptosis in normal thyroid cells and papillary thyroid carcinoma cells via extrinsic and intrinsic pathways. Endocrinology 2003, 144, 4172-4179.
93. Song, R. X.; Santen, R. J. Apoptotic action of estrogen. Apoptosis 2003, 8, 55-60.
94. Burow, M. E.; Tang, Y.; Collins-Burow, B. M.; Krajewski, S, Reed, J. C.; McLachlan, J. A.; Beckman, B. S. Effects of environmental estrogens on tumor necrosis factor -mediated apoptosis in MCF-7 cells. Carcinogenesis 1999, 20, 2057-2061.
95. Vakkala, M.; Lahteenmaki, K.; Raunio, H.; Paakko, P.; Soini, Y. Apoptosis during breast carcinoma progression. Clin. Cancer Res. 1999, 5, 319-324.
96. Burow, M. E.; Weldon, C. B.; Tang, Y.; Navar, G. L.; Krajewski, S.; Reed, J. C.; Hammond, T. G.; Clejan, S.; Beckman, B. S. Differences in susceptibility to tumor necrosis factor -induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res. 1998, 58, 4940-4946.
97. Roberts, P. J.; Der, C. J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26, 3291-310.
98. Dunn, K. L.; Espino, P. S.; Drobic, B.; He, S.; Davie, J. R. The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem. Cell Biol. 2005, 83, 1-14.
99. Chen, G. G.; Liu, Z. M.; Vlantis, A. C.; Tse, G. M. K.; Leung, B. C. H.; van Hasselt, C. A. Heme oxygenase-1 protects apoptosis induced by tumor necrosis factor-α and cycloheximide in thyroid papillary cell carcinoma. J. Cell. Biochem. 2004, 92, 1246-1256.
100. Liu, Z. M.; Chen, G. G.; Vlantis, A. C.; Liang, N. C.; Deng, Y. F.; van Hasselt, C. A. Cell death induced by ent-11α-hydroxy-15-oxo-kaur-16-en-19- oic-acid in anaplastic thyroid carcinoma cells is via a mitochondrial-mediated pathway. Apoptosis 2005, 10, 1345-1356.
101. Liu, Z. M.; Chen, G. G.; Vlantis, A. C.; Shum, C. K. Y.; van Hasselt, C. A. Calcium-mediated activation of PI3K/Akt and p53 leads to apoptosis in anaplastic thyroid carcinoma cells treated with cadmium, submitted. Cell. Mol. Life Sci. 2007, 64, 1428-1436.
102. Liu, Z. M.; Chen, G. G.; Shum, C. K. Y.; Vlantis, A. C.; Cherian, M. G.; van Hasselt, C. A. Transcriptional induction of functional MT1 and MT2 isoforms is calcium- and ERK-dependent in thyroid cancer cells. FEBS Lett. 2007, 581, 2465-2472.
103. Kondo, T.; Zheng, L.; Liu, W.; Kurebayashi, J.; Asa, S. L.; Ezzat, S. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res. 2007, 67, 5461-5470.
104. Lin, H. Y.; Tang, H. Y.; Shih, A.; Keating, T.; Cao, G.; Davis, P. J.; Davis, F. B. Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids 2007, 72, 180-187.
105. Xing, M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 2005, 12, 245-262.
106. Ball, D. W.; Jin, N.; Rosen, D. M.; Dackiw, A.; Sidransky, D.; Xing, M.; Nelkin, B. D. Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the MEK 1/2 Inhibitor AZD6244. J. Clin. Endocrinol. Metab. 2007, 92, 4712-4718.
107. De Bosscher, K.; Vanden Berghe, W.; Haegeman, G. Cross-talk between nuclear receptors and nuclear factor kappaB. Oncogene 2006, 25, 6868-6886.
108. Van Waes, C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin. Cancer Res. 2007, 13, 1076-1082.
109. Starenki, D.; Namba, H.; Saenko, V.; Ohtsuru, A.; Yamashita, S. Inhibition of nuclear factor-kappaB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells. J. Clin. Endocrinol. Metab. 2004, 89, 410-418.
110. Starenki, D. V.; Namba, H.; Saenko, V. A.; Ohtsuru, A.; Maeda, S.; Umezawa, K.; Yamashita, S. Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin. Cancer Res. 2004, 10, 6821-6829.
111. Kato, Y.; Ying, H.; Zhao, L.; Furuya, F.; Araki, O.; Willingham, M. C.; Cheng, S. Y. PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene 2006, 25, 2736-2747.
112. Palona, I.; Namba, H.; Mitsutake, N.; Starenki, D.; Podtcheko, A.; Sedliarou, I.; Ohtsuru, A.; Saenko, V.; Nagayama, Y.; Umezawa, K.; Yamashita, S. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinol. 2006, 147, 5699-5707.
113. Lobanova, Y. S.; Scherbakov, A. M.; Shatskaya, V. A.; Krasil'nikov, M. A.; Mechanism of estrogen-induced apoptosis in breast cancer cells: role of the NF-kappaB signaling pathway. Biochemistry 2007, 72, 320-327.
114. Feldman, I.; Feldman, G. M.; Mobarak, C.; Dunkelberg, J. C.; Leslie, K. K. Identification of proteins within the nuclear factor-kappa B transcriptional complex including estrogen receptor-alpha. Am. J. Obstet. Gynecol. 2007, 196, 394.e1-e11.
115. Jiang, J.; Slivova, V.; Sliva, D. Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling. Int. J. Oncol. 2006, 29, 695-703.
116. Olivier, S.; Close, P.; Castermans, E.; de Leval, L.; Tabruyn, S.; Chariot, A.; Malaise, M.; Merville, M. P.; Bours, V.; Franchimont, N. Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature. Mol. Pharmacol. 2006, 69, 1615-1623.
117. Chu, S.; Nishi, Y.; Yanase, T.; Nawata, H.; Fuller, P. J. Transrepression of estrogen receptor beta signaling by nuclear factor-kappab in ovarian granulosa cells. Mol. Endocrinol. 2004, 18, 1919-1928.